Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

According to the recently published report 'Tyrosine Protein Kinase JAK3 - Drugs In Development, 2022'; Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) pipeline Target constitutes close to 30 molecules. Out of which approximately 30 molecules are developed by Companies.

Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) - Tyrosine-protein kinase JAK3 is an enzyme encoded by the JAK3 gene. It is involved in various processes such as cell growth, development, or differentiation. Mediates essential signaling events in both innate and adaptive immunity and plays a crucial role in hematopoiesis during T-cells development. It plays a pivotal role in signal transduction via its association with type I receptors sharing the common subunit gamma such as IL2R, IL4R, IL7R, IL9R, IL15R and IL21R. Following ligand binding to cell surface receptors phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins.

The report 'Tyrosine Protein Kinase JAK3 - Drugs In Development, 2022' outlays comprehensive information on the Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 4, 4, 6, 15 and 1 respectively. Report covers products from therapy areas Immunology, Dermatology, Gastrointestinal, Musculoskeletal Disorders, Oncology, Respiratory, Infectious Disease, Cardiovascular, Ophthalmology, Central Nervous System and Genetic Disorders which include indications Rheumatoid Arthritis, Atopic Dermatitis (Atopic Eczema), Inflammatory Bowel Disease, Alopecia Areata, Ulcerative Colitis, Psoriasis, Asthma, Crohn's Disease (Regional Enteritis), Dermatitis (Eczema), Vitiligo, Arthritis, Celiac Disease, Diffuse Large B-Cell Lymphoma, Systemic Lupus Erythematosus, Allergic Conjunctivitis, Allergies, Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy, Ankylosing Spondylitis (Bekhterev's Disease), Autoimmune Disorders, B-Cell Chronic Lymphocytic Leukemia, B-Cell Non-Hodgkin Lymphoma, Cachexia, Chronic Cutaneous Lupus Erythematosus (CCLE) / Discoid Lupus Erythematosus (DLE), Chronic Granulomatous Disease, Chronic Obstructive Pulmonary Disease (COPD), Colitis, Colorectal Cancer, Coronavirus Disease 2019 (COVID-19), Coronavirus Disease 2019 (COVID-19) Associated Cytokine Release Syndrome, Coronavirus Disease 2019 (COVID-19) Pneumonia, Cutaneous T-Cell Lymphoma, Dermatomyositis, Dermatosis, Fibrosis, Follicular Lymphoma, Graft Versus Host Disease (GVHD), Hand Dermatitis, Idiopathic Pulmonary Fibrosis, Inflammation, Ischemia Reperfusion Injury, Keratoconjunctivitis Sicca (Dry Eye), Mantle Cell Lymphoma, Marginal Zone B-cell Lymphoma, Multiple Sclerosis, Pemphigus Vulgaris, Peripheral T-Cell Lymphomas (PTCL), Plaque Psoriasis (Psoriasis Vulgaris), Polyarticular Juvenile Idiopathic Arthritis (PJIA), Pouchitis, Psoriatic Arthritis, Pulmonary Arterial Hypertension, Sarcoidosis, Sarcopenia, Sicca Syndrome (Sjogren), Systemic Sclerosis (Scleroderma) and Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma).

Note:Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

• The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
• The report reviews Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) targeted therapeutics

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK3 (Janus Kinase 3 or Leukocyte Janus Kinase or JAK3 or EC 2.7.10.2) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies Mentioned
Companies Mentioned

Aclaris Therapeutics Inc
Alexion Pharmaceuticals Inc
Arrien Pharmaceuticals LLC
Astellas Pharma Inc
Bristol-Myers Squibb Co
Celon Pharma SA
Clevexel Pharma SA
Daewoong Pharmaceutical Co Ltd
Guangdong Zhongsheng Pharmaceutical Co Ltd
Impetis Biosciences Ltd
Japan Tobacco Inc
KBP Biosciences Co Ltd
Kinaset Therapeutics Inc
MedAvail Holdings Inc
Merck & Co Inc
Oncostellae SL
Pfizer Inc
Shenzhen Chipscreen Biosciences Co Ltd
Simcere Pharmaceutical Group Ltd
Theravance Biopharma Inc